Aurinia Pharmaceuticals Inc.
AUPH
$8.18
$0.080.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 59.87M | 67.77M | 57.19M | 50.30M | 45.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.87M | 67.77M | 57.19M | 50.30M | 45.10M |
| Cost of Revenue | 13.66M | 9.08M | 12.99M | 13.30M | 15.62M |
| Gross Profit | 46.21M | 58.69M | 44.20M | 37.00M | 29.47M |
| SG&A Expenses | 37.03M | 42.37M | 44.93M | 47.70M | 50.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.39M | 4.57M | -290.00K | -4.13M | 3.17M |
| Total Operating Expenses | 52.09M | 56.02M | 57.63M | 56.87M | 68.87M |
| Operating Income | 7.78M | 11.75M | -441.00K | -6.57M | -23.77M |
| Income Before Tax | 1.17M | 14.81M | 1.48M | -10.01M | -26.42M |
| Income Tax Expenses | -256.00K | 457.00K | 756.00K | 739.00K | 459.00K |
| Earnings from Continuing Operations | 1.43M | 14.35M | 722.00K | -10.75M | -26.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.43M | 14.35M | 722.00K | -10.75M | -26.88M |
| EBIT | 7.78M | 11.75M | -441.00K | -6.57M | -23.77M |
| EBITDA | 12.64M | 16.64M | 4.40M | -1.72M | -18.83M |
| EPS Basic | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 |
| Normalized Basic EPS | 0.07 | 0.06 | 0.01 | -0.01 | -0.12 |
| EPS Diluted | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 |
| Normalized Diluted EPS | 0.07 | 0.06 | 0.01 | -0.01 | -0.12 |
| Average Basic Shares Outstanding | 142.18M | 143.05M | 143.33M | 144.01M | 142.93M |
| Average Diluted Shares Outstanding | 147.68M | 145.65M | 144.11M | 144.01M | 142.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |